Azenosertib

Phase 3Small molecule

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib is one of 112 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Primary Peritoneal CancerRecruiting

Clinical Stage III Gastric Cancer AJCC V8Recruiting

Locally Advanced Pancreatic Ductal AdenocarcinomaRecruiting

Serous CarcinomaRecruiting

PembrolizumabActive, not recruiting

Ovarian CancerPhase 3

Recruiting

Primary Peritoneal CancerPhase 2

Recruiting

Clinical Stage III Gastric Cancer AJCC V8Phase 1

Recruiting

Locally Advanced Pancreatic Ductal AdenocarcinomaPhase 1

Recruiting

Serous CarcinomaPhase 2

Recruiting

PembrolizumabPhase 2

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Hycamtin

MMeitheal

Phase 3

26 4

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 5

Femara

Novartis

Phase 3

8 6

Imfinzi

AstraZeneca

Phase 3

8 7

Opdivo

Bristol-Myers Squibb

Phase 3

8 8

Adriamycin

Pfizer

Phase 3

8 9

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Zepzelca

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Primary Peritoneal Cancer

NCT05128825

Q3 2027

Phase 1Recruiting

Clinical Stage III Gastric Cancer AJCC V8

NCT06364410

Q1 2028

Phase 2Recruiting

Serous Carcinoma

NCT06369155

Phase 1Recruiting

Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT04005690

Q3 2029

Phase 1/2Active, not recruiting

Pembrolizumab

NCT06351332

Clinical

Trials by Indication[1]

Serous Carcinoma2 trials

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

Recruiting·—·Phase 2·NCT06369155·25 enrolled

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT04814108·92 enrolled

Ovarian Cancer2 trials

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT05198804·117 enrolled

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 3·NCT07546500·420 enrolled

Pembrolizumab1 trial

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Active, not recruiting·FFilipa Lynce, MD·Phase 1/2·NCT06351332·78 enrolled

Solid Tumors1 trial

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1·NCT04158336·274 enrolled

Osteosarcoma1 trial

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Completed·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1/2·NCT04833582·31 enrolled

3 more indications

Locally Advanced Pancreatic Ductal Adenocarcinoma1 trial

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT04005690·90 enrolled

Clinical Stage III Gastric Cancer AJCC v81 trial

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06364410·48 enrolled

Primary Peritoneal Cancer1 trial

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 2·NCT05128825·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Azenosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azenosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azenosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Azenosertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Serous Carcinoma2 trials

Ovarian Cancer2 trials

Pembrolizumab1 trial

Solid Tumors1 trial

Osteosarcoma1 trial

Locally Advanced Pancreatic Ductal Adenocarcinoma1 trial

Clinical Stage III Gastric Cancer AJCC v81 trial

Primary Peritoneal Cancer1 trial

References

Drug Info

Quick Facts

Related News